It's not just pricing and patenting. Now, AbbVie's taxes are the target of congressional scrutiny

AbbVie has spent years responding to a congressional probe over its drug pricing and patenting strategies, with the findings just becoming public late last month. Now, in a newly unveiled probe, congressional Democrats are zeroing in on the company's tax payments.